CYLD expression in dendritic cells involved in the immunoregulation of pulmonary adenocarcinoma via NF-κB pathway
Source abstract
Abstract
Our previous study found that IL33 repressed the growth of pulmonary adenocarcinoma (PA) via regulation of dendritic cells (DCs). However, the molecular mechanism of DCs in PA is still unclear. The present work showed that CYLD−/− mice have a shorter survival rate of PA, and knockout CYLD in DCs also repress the progression of PA in mice. Subsequently, we found that decreased expression and reduced the nuclear translocation of NF-κB signalling was observed in CYLD knockout DCs, and inhibiting NF-κB pathway repressed DCs-induced proliferation and function of CD4+ T cells. These results indicated that CYLD function as a tumour suppresser in PA via regulates the function of DCs through NF-κB signalling pathway. Our findings support that CYLD serves as a potential target for immunotherapy in PA.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Immunotherapy and Immune Responses · Cancer-related molecular mechanisms research · NF-κB Signaling Pathways
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Radiology, Fujian Provincial Hospital, Provincial Clinical College of Fujian Medical University
Department of Thoracic Surgery, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University
Department of Thoracic Surgery, Fujian Provincial Hospital, Provincial Clinical College of Fujian Medical University
References (33)
Show source-provided references
1. 10.1158/2326-6066.CIR-17-065510.1158/2326-6066.CIR-17-0655 ↗
2. 10.1038/ncomms160910.1038/ncomms1609 ↗
3. 10.1158/0008-5472.CAN-17-130710.1158/0008-5472.CAN-17-1307 ↗
4. 10.1038/srep4539510.1038/srep45395 ↗
5. 10.1158/1078-0432.CCR-16-282110.1158/1078-0432.CCR-16-2821 ↗
6. 10.1186/s13046-015-0126-910.1186/s13046-015-0126-9 ↗
7. 10.1016/j.jep.2019.11198010.1016/j.jep.2019.111980 ↗
8. 10.1039/C9NR03510A10.1039/C9NR03510A ↗
9. 10.1080/21691401.2019.159692610.1080/21691401.2019.1596926 ↗
10. 10.1038/cddis.2011.8210.1038/cddis.2011.82 ↗
11. 10.7150/thno.1084410.7150/thno.10844 ↗
12. 10.1038/leu.2011.35710.1038/leu.2011.357 ↗
13. 10.1093/carcin/bgl08110.1093/carcin/bgl081 ↗
14. 10.1093/carcin/bgt33510.1093/carcin/bgt335 ↗
15. 10.1016/j.immuni.2007.07.01110.1016/j.immuni.2007.07.011 ↗
16. Zhang LM, Zhou JJ, Luo CL. CYLD suppression enhances the pro-inflammatory effects and hyperproliferation of rheumatoid arthritis fibroblast-like synoviocytes by enhancing NF-kappaB activation. Arthritis Res Ther. 2018;20(1):219.
17. 10.1053/j.gastro.2018.10.02310.1053/j.gastro.2018.10.023 ↗
18. 10.3389/fimmu.2015.0065010.3389/fimmu.2015.00650 ↗
19. 10.1016/j.celrep.2016.05.03210.1016/j.celrep.2016.05.032 ↗
20. 10.1182/blood-2008-08-17548910.1182/blood-2008-08-175489 ↗
21. 10.1038/s41419-018-0889-y10.1038/s41419-018-0889-y ↗
22. 10.1038/cdd.2009.4310.1038/cdd.2009.43 ↗
23. 10.1038/leu.2017.16810.1038/leu.2017.168 ↗
24. 10.1158/2326-6066.CIR-17-011710.1158/2326-6066.CIR-17-0117 ↗
25. 10.1080/2162402X.2018.143108410.1080/2162402X.2018.1431084 ↗
26. 10.1016/j.jtho.2017.10.02010.1016/j.jtho.2017.10.020 ↗
27. 10.1007/s00005-011-0157-710.1007/s00005-011-0157-7 ↗
28. 10.1016/j.yexcr.2019.11149710.1016/j.yexcr.2019.111497 ↗
29. 10.1371/journal.ppat.100743510.1371/journal.ppat.1007435 ↗
30. 10.1016/j.cell.2006.03.04110.1016/j.cell.2006.03.041 ↗
31. Li Y, Huang W, Xu Y, et al. CYLD deubiquitinase negatively regulates high glucose-induced NF-kappaB inflammatory signaling in mesangial cells. BioMed Res Int. 2017;2017:1.10.1155/2017/3982906 ↗
32. 10.3389/fnmol.2017.0036310.3389/fnmol.2017.00363 ↗
33. 10.4049/jimmunol.120199310.4049/jimmunol.1201993 ↗